Navigation Links
Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
Date:9/12/2007

STEWARTVILLE, Minn., Sept. 12 /PRNewswire-FirstCall/ -- Rochester Medical Corporation (Nasdaq: ROCM) announced today the publication of results from a significant clinical study which further demonstrates the effectiveness of the Company's proprietary Infection Control Technology.

The newly released September issue of the "Annals of Internal Medicine" presents results of a randomized, double-blind, controlled clinical trial involving 212 adult patients at Denmark's Copenhagen Trauma Center. The study concluded nitrofurazone-impregnated urinary catheters reduced the incidence of catheter-associated bacteriuria and funguria in adult trauma patients, reducing the need to change or prescribe new antimicrobial therapy.

The nitrofurazone-impregnated urinary catheters used in the study were manufactured by Rochester Medical. The control catheter was an all-silicone Foley catheter. The study was conducted by Jakob Stensballe, PhD; Michael Tvede, MD; Dagnia Looms, PhD; Freddy Knudsen Lippert, MD; Benny Dahl, DMSc; Else Tonnesen, DMSc; and Lars Simon Rasmussen, PhD.

Commenting on the peer-reviewed publication of this clinical study, Rochester Medical's CEO and President - Anthony J. Conway said, "This is more good news in the ongoing effort to reduce serious infections in hospitals around the world. There is now published data from the United States, Denmark, South Korea, Spain, and Saudi Arabia showing the effectiveness of our All Silicone Anti-Infection Foley Catheters."

Conway continued, "Hospital acquired infections are a serious problem across the globe. In the United States alone it is estimated these infections cause over 90,000 deaths a year. The Center for Disease Control estimates 40% of all hospital acquired infections are urinary tract infections resulting from Foley catheterization.

As further demonstrated by Dr. Stensballe and his colleagues, these serious infections can be significantly reduced by use of our advanced Release-NF(R) technology. Our team at Rochester Medical is working vigorously to ensure clinicians throughout the world get the message about how our nitrofurazone-impregnated Foley catheters reduce infections. Some major medical institutions already are embracing these benefits and using the Rochester Medical Release-NF catheters."

Conway also noted, "Hospital acquired infections are coming under heightened scrutiny, with the aim that increased attention will lead to improvements and solutions. States are legislating that hospitals publicly post data defining their incidence of hospital acquired infections. Medicare recently finalized new reimbursement rules that will eliminate payments to hospitals to cover the cost of catheter-associated urinary tract infections.

"We believe Rochester Medical's All-Silicone Anti-Infection Foley catheters will play a pivotal role in helping reduce these infections. While costs can be significantly decreased, most importantly, serious illness can be prevented. It is very gratifying to continue to see new scientific studies that inform clinicians and reaffirm the effectiveness of our products. Everyone at Rochester Medical is very proud and motivated to be technology leaders in the crucial fight against hospital acquired infections."

This press release contains forward-looking statements that involve risks and uncertainties, including the uncertainty of estimated revenues and profits, as well as the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of private label sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2006.

Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications. The Company markets under its own Rochester Medical(R) brand and under existing private label arrangements.

For further information, please contact Anthony J. Conway, President and Chief Executive Officer of Rochester Medical Corporation at (507) 533-9600. More information about Rochester Medical is available on its website at http://www.rocm.com.


'/>"/>
SOURCE Rochester Medical Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
10. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
11. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... 2017 Three Tru-D SmartUVC robots have arrived at ... . Tru-D, short for "Total Room Ultraviolet Disinfection," is a 5-foot-5 ... environmental services (ES) professional cleans the area with traditional cleaning protocols. ... Tru-D fights germs at ... "Although the BAACH has a very low ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
(Date:7/26/2017)... 26, 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) ... trial evaluating Altemia TM , an oral therapy for ... Cell Disease (SCD). The SCOT Trial, is a double-blind, ... safety of Altemia TM in pediatric patients aged ... IND 125274. "The ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... Five Star Glass is new to the Texas market, but ... of auto glass for most makes and models, in Grand Prairie, TX, located in the ... They have been a family owned business for the past 40 years with 32 convenient ...
(Date:8/22/2017)... ... , ... “Glimpses Of Light”: is a unique and thought inspiring guide ... creation of published author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author ... , Shepherd shares, “Love is one of the least understood and yet most sought-after ...
(Date:8/21/2017)... MO (PRWEB) , ... August 22, 2017 , ... PracticeMatch, ... fairs to help healthcare employers connect with physicians and advanced practitioners like nurse ... virtual career fairs in August through November of this year. The online career ...
(Date:8/21/2017)... ... 2017 , ... SportsEngine, Inc. , a division of ... of North Country Region Volleyball and will power registration, scheduling, and competition results ... sport management software to their member clubs. , SportsEngine provides financial ...
(Date:8/21/2017)... ... , ... PIXACORE , an independent full-service agency with a decade of ... the year by MM&M. , This is the first time PIXACORE has made the ... agency. PIXACORE’s newfound recognition reflects its steady trajectory of growth and recent strategic ...
Breaking Medicine News(10 mins):